Loading...
XSHE002872
Market cap200mUSD
Dec 24, Last price  
4.58CNY
1D
-4.97%
1Q
24.73%
IPO
-80.29%
Name

Tiansheng Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:002872 chart
P/E
—
P/S
2.51
EPS
—
Div Yield, %
1.07%
Shrs. gr., 5y
5.14%
Rev. gr., 5y
-23.22%
Revenues
579m
-4.56%
1,004,120,0191,421,960,0591,663,784,3431,843,015,2802,086,931,5572,261,414,3762,171,439,9231,678,052,4661,202,746,111736,685,771606,992,213579,334,659
Net income
-93m
109,987,794125,948,051164,573,145191,977,863224,496,958248,575,37615,621,1870000-93,073,691
CFO
-25m
L
145,057,10057,059,300191,988,710213,538,862506,677,2400153,986,687144,208,286189,754,32918,971,79289,184,806-24,561,761
Dividend
Aug 22, 20180.236 CNY/sh
Earnings
May 16, 2025

Profile

Tiansheng Pharmaceutical Group Co., Ltd. engages in the pharmaceutical manufacturing and circulation activities. It offers products in various categories, including respiratory, digestive, cardiovascular and cerebrovascular, pediatric, gynecological, orthopedic, tumor, hepatobiliary, blood, surgery, diabetes, and others. The company was founded in 2001 and is based in Chongqing, China.
URL
https://www.tszy.com.cn/
IPO date
May 19, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
579,335
-4.56%
606,992
-17.61%
736,686
-38.75%
Cost of revenue
566,527
600,911
722,728
Unusual Expense (Income)
NOPBT
12,808
6,081
13,957
NOPBT Margin
2.21%
1.00%
1.89%
Operating Taxes
(1,011)
7,437
17,895
Tax Rate
122.31%
128.21%
NOPAT
13,818
(1,356)
(3,938)
Net income
(93,074)
 
Dividends
(15,537)
(22,895)
Dividend yield
0.95%
1.38%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
200,318
236,349
185,847
Long-term debt
67,094
35,534
174,664
Deferred revenue
127,794
126,338
131,463
Other long-term liabilities
66,178
67,250
68,947
Net debt
22,001
(127,120)
(60,165)
Cash flow
Cash from operating activities
(24,562)
89,185
18,972
CAPEX
(76,738)
Cash from investing activities
(82,080)
169,580
Cash from financing activities
(11,204)
FCF
17,166
16,350
379,341
Balance
Cash
192,712
278,250
420,676
Long term investments
52,700
120,754
Excess cash
216,445
368,654
383,841
Stockholders' equity
553,161
786,813
878,458
Invested Capital
2,335,763
2,259,089
2,439,478
ROIC
0.60%
ROCE
0.50%
0.23%
0.49%
EV
Common stock shares outstanding
318,000
318,000
318,000
Price
5.13
-2.84%
5.28
1.15%
5.22
10.13%
Market cap
1,631,340
-2.84%
1,679,040
1.15%
1,659,960
10.13%
EV
1,657,518
1,556,736
1,605,601
EBITDA
120,067
113,803
103,950
EV/EBITDA
13.80
13.68
15.45
Interest
14,994
15,784
24,356
Interest/NOPBT
117.07%
259.57%
174.50%